

Appl. No. : 10/805,386  
Filed : March 22, 2004

## SUMMARY OF INTERVIEW

### Exhibits and/or Demonstrations

None

### Identification of Claims Discussed

19, 21-35, and 37-48, i.e., all of the pending claims and the proposed new claims.

### Identification of Prior Art Discussed

Lord et al. (USP 6,417,227), WO 00/85162, and Diehl (USP 4,113,881).

### Proposed Amendments

Applicants proposed to include a listing of excipients or carriers as a Markush group and a listing of cetylated fatty acids as a Markush group in claim 19.

### Principal Arguments and Other Matters

Applicants argued that the art taught away from the use of anti-inflammatory drugs for the treatment of periodontal disease and that there was long felt and unmet need for a useful anti-inflammatory drug, as evidenced by the Van Dyke Declaration (a draft of which was presented to the Examiner). Applicants further argued that the specification provided sufficient enablement for a composition comprising a cetylated fatty acid, selected from the list provided in Table 3 of the specification, and a carrier or excipients, as disclosed in the specification.

### Results of Interview

The Examiner suggested that the proposed amendments, in conjunction with the Van Dyke Declaration and Applicants' other arguments, will be looked upon favorably.